Novocure LTD Form 4 insider transactions

Ben Arye Barak, General Counsel of NovoCure Ltd, reports the acquisition and disposal of ordinary shares and stock options.

Michal Nath Puri, Chief Human Resources Officer at NovoCure, reports acquisition of shares and stock options.

Uri Weinberg, Chief Innovation Officer of NovoCure Ltd, reports acquisition of shares and stock options.

Frank X. Leonard, EVP and President of Novocure Oncology, reports acquisition of shares and options in NovoCure Ltd.

NovoCure's Chief Operating Officer, Mukund Paravasthu, reports the acquisition of shares and stock options.

Chief Executive Officer Ashley Cordova reports acquiring shares and stock options in NovoCure Ltd.

Chief Financial Officer Christoph Brackmann reports acquisition of NovoCure shares and stock options in a recent SEC filing.

Uri Weinberg, Chief Innovation Officer of NovoCure Ltd, sold 268 shares of ordinary stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Frank X. Leonard, EVP and President of Novocure Oncology, sold 2,527 ordinary shares of NovoCure Ltd to cover tax withholding obligations related to the vesting of Restricted Stock Units.

NovoCure's CEO, Ashley Cordova, sold 2,053 shares of company stock on March 3, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

Mukund Paravasthu, Chief Operating Officer of NovoCure Ltd, sold 250 shares to cover tax withholding obligations related to vesting Restricted Stock Units.

Uri Weinberg, Chief Innovation Officer of NovoCure, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

NovoCure's CEO, Ashley Cordova, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Frank Leonard, EVP and President of Novocure Oncology, sold shares of NovoCure Ltd to cover tax withholding obligations related to vesting Restricted Stock Units.

Michal Nath Puri, Chief Human Resources Officer of NovoCure Ltd, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units.

Nicolas Leupin, Chief Medical Officer of NovoCure Ltd, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units.

NovoCure's Chief Operating Officer, Mukund Paravasthu, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units.

Uri Weinberg, Chief Innovation Officer of NovoCure Ltd, reported the sale of company stock on February 28, 2025, according to a Form 4 filing with the SEC.

Nicolas Leupin, Chief Medical Officer of NovoCure, sold a portion of his holdings in the company's ordinary shares on February 27, 2025.

Michal Nath Puri, Chief Human Resources Officer of NovoCure Ltd, sold a total of 1,387 ordinary shares on February 27, 2025, at weighted average prices of $19.9219 and $20.549.

Frank Leonard, EVP and President of Novocure Oncology, sold a total of 14,986 NovoCure Ltd shares in multiple transactions on February 27 and 28, 2025.

NovoCure's CEO, Ashley Cordova, recently sold a portion of her holdings in the company's ordinary shares across multiple transactions.

NovoCure's Chief Operating Officer, Mukund Paravasthu, reported the sale of company stock in multiple transactions on February 27 and 28, 2025.

Mukund Paravasthu, Chief Operating Officer of NovoCure Ltd, sold 2,160 ordinary shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Barak Ben Arye, General Counsel of NovoCure, reports acquisition of company shares through the Employee Share Purchase Plan.

CEO Ashley Cordova reports acquiring 373 ordinary shares of NovoCure Ltd. through the company's Employee Share Purchase Plan (ESPP) at a price of $14.748 per share.

Director Asaf Danziger reports acquisition of NovoCure shares through an employee share purchase plan and vesting of restricted share units.

NovoCure's Chief Operating Officer, Mukund Paravasthu, reported the sale of shares to cover tax obligations and the acquisition of restricted share units and stock options.

Michal Nath Puri, Chief Human Resources Officer of NovoCure Ltd, sold 810 ordinary shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Frank X. Leonard, EVP and President of Novocure Oncology, sold 598 shares of NovoCure Ltd to cover tax withholding obligations related to vesting Restricted Stock Units.